United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - von willebrand factor - powder and solvent for solution for injection - 1000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - human fibrinogen - powder and solvent for solution for infusion - 1.5gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - normal immunoglobulin human - solution for infusion - 100mg/1ml

United States - English - NLM (National Library of Medicine)

lfb usa, inc. - bc2371 rdna construct on chromosome 3p1.1-2 in r69 new zealand white rabbits (unii: 00pr6az7su) (bc2371 rdna construct on chromosome 3p1.1-2 in r69 new zealand white rabbits - unii:00pr6az7su) - the r69 line of new zealand white rabbits in the united states must be housed in only the lfb usa, inc. facilities specified in the approved application. manufactured by: lfb usa 175 crossing boulevard framingham, ma 01702 approved by fda under nada 141-511

United States - English - NLM (National Library of Medicine)

lfb usa, inc. - bc6 rdna construct on chromosome 5q3.4 in 155-92 goats (unii: 79kf6nse5j) (bc6 rdna construct on chromosome 5q3.4 in 155-92 goats - unii:79kf6nse5j) - the 155-92 goats in the united states must be housed in only the lfb usa facility specified in the approved application. manufactured by: lfb usa, inc. 175 crossing boulevard framingham, ma 01702 approved by fda under nada 141-294

United States - English - NLM (National Library of Medicine)

laboratoire français du fractionnement et des biotechnologies société anonyme (lfb s.a.) - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - sevenfact  [coagulation factor viia (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia a or b with inhibitors.  limitation of use: sevenfact is not indicated for the treatment of patients with congenital factor vii deficiency. sevenfact is contraindicated in - known allergy to rabbits or rabbit proteins. exposure to sevenfact in these patients can result in severe hypersensitivity reaction.  - patients with severe hypersensitivity reaction to sevenfact or any of its components. exposure to sevenfact in these patients can result in severe hypersensitivity reaction.  risk summary there are no adequate and well-controlled studies using sevenfact in pregnant women to determine whether there is a drug-associated risk. animal studies evaluating the embryo-fetal teratogenic potential of sevenfact have not been conducted. it is unknown whether sevenfact can cause fetal harm when administered to a pregnant

Egypt - English - EDA (Egyptian Drug Authority)

biovax egypt - injection - 100 mcg/2ml